Ryvu Therapeutics (WSE: RVU), a Poland-based clinical-stage drug discovery and development company, announced on Monday that it has named Vatnak Vat-Ho as its new chief business officer.
In the new role, Vat-Ho will be responsible for a wide scope of corporate and business development activities at Ryvu, including strategic positioning, partnering discussions, alliance management as well as investor interactions.
Vat-Ho has around 20 years of professional experience including pharma, biotech and capital markets expertise. He spent the first 10 years of his professional career in various investment banks and global equity healthcare funds, later moving to the pharma and biotech industry. He has served in various roles at Pfizer. He has also served as vice president, Business Development at Affimed Inc.
Bioforum, The Data Masters names new President
VolitionRx names new Chief Medical Officer
Quotient Sciences announces new appointments
Syndax Pharmaceuticals names new chief commercial officer
Everest Medicines names new chief medical officer and chief product officer
D3 Bio names new independent board member
Rigel Pharmaceuticals names new executive vice president and chief medical officer
Telix Pharmaceuticals names new group chief operating officer